Premium
Outline of JUA clinical guidelines for benign prostatic hyperplasia
Author(s) -
Homma Yukio,
Gotoh Momokazu,
Yokoyama Osamu,
Masumori Naoya,
Kawauchi Akihiro,
Yamanishi Tomonori,
Ishizuka Osamu,
Seki Narihito,
Kamoto Toshiyuki,
Nagai Atsushi,
Ozono Seiichiro
Publication year - 2011
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.2011.02860.x
Subject(s) - medicine , lower urinary tract symptoms , hyperplasia , bladder outlet obstruction , urology , prostate , urinalysis , finasteride , overactive bladder , physical examination , transrectal ultrasonography , medical history , rectal examination , prostate specific antigen , benign prostatic hyperplasia (bph) , urinary system , pathology , alternative medicine , cancer
The Japanese Urological Association has developed Clinical Guidelines for Benign Prostatic Hyperplasia (BPH) for men with suspected BPH, which have been abridged and translated into English. This article is a shortened version of the English translation. The Guidelines were formulated on the basis of evidence retrieved from the PubMed database between 1995 and 2009, as well as other relevant sources. The target patients of these Guidelines are men with suspected BPH, and the target users are urologists. A mandatory assessment should include a medical history, a physical examination, the completion of symptom and quality of life questionnaires, urinalysis, prostate ultrasonography, measurement of serum prostate specific antigen and postvoid residual urine, and an uroflowmetry. Optional tests include a bladder diary, the measurement of serum creatinine, and upper urinary tract ultrasonography. Care should be taken to not overlook coexisting diseases such as an infection or malignancy that may obscure the diagnosis. Treatment should consist of conservative therapy or the use of medications such as α 1 ‐adrenoceptor antagonists, or both. The use of 5α‐reductase inhibitors or anticholinergic agents should be considered in patients with an enlarged prostate (>30 mL) or overactive bladder symptoms (overactive bladder symptom score ≥6), respectively. Surgical intervention is indicated when non‐surgical treatments fail to provide sufficient symptomatic relief and bladder outlet obstruction is highly suspected.